» Articles » PMID: 29943908

Meeting Report of the STAR-Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ Subgroup Focus on Kidney Transplantation

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2018 Jun 27
PMID 29943908
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The development of de novo donor-specific HLA antibody (dnDSA) is a critical feature contributing to late allograft failure. The complexity of the issue is further complicated by organ-specific differences, detection techniques, reliance of tissue histopathology and changing diagnostic criteria, ineffective therapies, and lack of consensus. To tackle these issues, the Sensitization in Transplantation Assessment of Risk (STAR) 2017 was initiated as a collaboration of the American Society of Transplantation and American Society of Histocompatibility and Immunogenetics consisting of 8 working groups with the goal to provide guidelines on how to assess risk and risk stratify patients based on their potential alloimmune and DSA status. Herein is a summary of discussions by the Naïve Abdominal Working Group, highlighting currently available data and identifying gaps in our knowledge on the development and impact of dnDSA following kidney transplantation.

Citing Articles

Early progression of chronic histologic lesions in kidney transplant biopsies is not associated with HLA histocompatibility.

Jabbour R, Heinzel A, Reindl-Schwaighofer R, Gregorich M, Regele H, Kozakowski N Nephrol Dial Transplant. 2023; 39(5):808-817.

PMID: 37960919 PMC: 11181859. DOI: 10.1093/ndt/gfad246.


Surrogate Endpoints for Late Kidney Transplantation Failure.

Naesens M, Budde K, Hilbrands L, Oberbauer R, Bellini M, Glotz D Transpl Int. 2022; 35:10136.

PMID: 35669974 PMC: 9163814. DOI: 10.3389/ti.2022.10136.


Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort.

Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E Am J Transplant. 2020; 21(1):322-328.

PMID: 32888256 PMC: 7821185. DOI: 10.1111/ajt.16290.


Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial.

Mannon R, Armstrong B, Stock P, Mehta A, Farris A, Watson N Am J Transplant. 2020; 20(12):3599-3608.

PMID: 32558199 PMC: 7710570. DOI: 10.1111/ajt.16152.


HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity.

Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson I, Ho J, Birk P Am J Transplant. 2018; 19(6):1708-1719.

PMID: 30414349 PMC: 6563434. DOI: 10.1111/ajt.15177.